Preliminary physiologically based pharmacokinetic models for benzo[a]pyrene and dibenzo[def,p]chrysene in rodents

Toxicology and Applied Pharmacology

Volumn 257, Issue 3, 2011, Pages 365-376

  Crowell, Susan Ritger ^a   Amin, Shantu G ^b   Anderson, Kim A ^c   Krishnegowda, Gowdahalli ^b   Sharma, Arun K ^b   Soelberg, Jolen J ^a   Williams, David E ^c   Corley, Richard A ^a  

^a PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c OREGON STATE UNIVERSITY   (United States)

Author keywords

Benzo a pyrene; Dibenzo def,p chrysene; PBPK modeling; Polycyclic aromatic hydrocarbons

Indexed keywords

BENZO[A]PYRENE; CARCINOGEN; CHRYSENE DERIVATIVE; DIBENZO[DEF,P]CHRYSENE; FAT; UNCLASSIFIED DRUG; BENZO[A]PYRENE DERIVATIVE; DIBENZO(A,L)PYRENE;

ALGORITHM; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL BLOOD; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL MODEL; FEMALE; INTESTINE; LIVER; LIVER METABOLISM; LUNG; MALE; MOUSE; NONHUMAN; PARTITION COEFFICIENT; TISSUE PERFUSION; TRANSPLACENTAL CARCINOGENESIS; VENOUS BLOOD; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; POLLUTANT; RAT; SPRAGUE DAWLEY RAT; TISSUE DISTRIBUTION;

RODENTIA;

ADMINISTRATION, ORAL; ALGORITHMS; ANIMALS; BENZO(A)PYRENE; BENZOPYRENES; ENVIRONMENTAL POLLUTANTS; FEMALE; INJECTIONS, INTRAVENOUS; MICE; MODELS, BIOLOGICAL; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84855744452     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2011.09.020     Document Type: Article

References (51)

1. Aarstad K., Toftgard R., Nilsen O.G. A comparison of the binding and distribution of benzo[a]pyrene in human and rat serum. Toxicology 1987, 47:235-245.
2. Baan R., Grosse Y., Straif K., Secretan B., El Ghissassi F., Bouvard V., Benbrahim-Tallaa L., Guha N., Freeman C., Galichet L., Cogliano V. A review of human carcinogens, Part F: Chemical agents and related occupations. Lancet Oncol. 2009, 10:1143-1144.
3. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg L.R., Beliles R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Heal. 1997, 13:407-484.
4. Buesen R., Mock M., Seidel A., Jacob J., Lampen A. Interaction between metabolism and transport of benzo[a]pyrene and its metabolites in enterocytes. Toxicol. Appl. Pharmacol. 2002, 183:168-178.
5. Castro D.J., Baird W.M., Pereira C.B., Giovanini J., Lohr C.V., Fischer K.A., Yu Z., Gonzalez F.J., Krueger S.K., Williams D.E. Fetal mouse CYP1b1 and transplacental carcinogenesis from maternal exposure to dibenzo(a, l)pyrene. Cancer Prev. Res. 2008, 1:128-134.
6. Cavalieri E.L., Rogan E.G., Higginbotham S., Cremonesi P., Salmasi S. Tumor-initiating activity in mouse skin and carcinogenicity in rat mammary-gland of dibenzo[a]pyrenes - the very potent environmental carcinogen dibenzo[a, l]pyrene. J. Cancer Res. Clin. Oncol. 1989, 115:67-72.
7. Cavalieri E.L., Higginbotham S., Ramakrishna N.V.S., Devanesan P.D., Todorovic R., Rogan E.G., Salmasi S. Comparative dose-response tumorigenicity studies of dibenzo[a, l]pyrene versus 7,12-dimethylbenz[a]anthracene, benzo[a]pyrene and 2 dibenzo[a, l]pyrene dihydrodiols in mouse skin and rat mammary-gland. Carcinogenesis 1991, 12:1939-1944.
8. Chiang K.-C., Liao C.-M. Heavy incense burning in temples promotes exposure risk from airborne PMs and carcinogenic PAHs. Sci. Total. Environ. 2006, 372:64-75.
9. Ciffroy P., Tanaka T., Johansson E., Brochot C. Linking fate model in freshwater and PBPK model to assess human internal dosimetry of B(a)P associated with drinking water. Environ. Geochem. Heal. 2011, 1-17.
10. Conney A.H. Induction of microsomal-enzymes by foreign chemicals and carcinogenesis by polycyclic aromatic-hydrocarbons - Clowes, G.H.A Memorial Lecture. Cancer Res. 1982, 42:4875-4917.
11. Dey A., Jones J.E., Nebert D.W. Tissue- and cell type-specific expression of cytochrome P450 1A1 and cytochrome P450 1A2 mRNA in the mouse localized in situ hybridization. Biochem. Pharmacol. 1999, 58:525-537.
12. Emond C., Birnbaum L.S., DeVito M.J. Use of a physiologically based pharmacokinetic model for rats to study the influence of body fat mass and induction of CYP1A2 on the pharmacokinetics of TCDD. Environ. Heal. Perspect. 2006, 114:1394-1400.
13. Fisher J., Todd P., Mattie D., Godfrey D., Narayanan L., Yu K. Preliminary development of a physiological model for perchlorate in the adult male rat: a framework for further studies. Drug Chem. Toxicol. 2000, 23:243-258.
14. Foth H., Kahl R., Kahl G.F. Pharmacokinetics of low-doses of benzo[a]pyrene in the rat. Food Chem. Toxicol. 1988, 26:45-51.
15. Gelboin H.V. Benzo[a]pyrene metabolism, activation, and carcinogenesis - role and regulation of mixed-function oxidases and related enzymes. Physiol. Rev. 1980, 60:1107-1166.
16. Haddad S., Withey J., Lapare S., Law F., Krishnan K. Physiologically-based pharmacokinetic modeling of pyrene in the rat. Environ. Toxicol. Pharmacol. 1998, 5:245-255.
17. Higginbotham S., Ramakrishna N.V.S., Johansson S.L., Rogan E.G., Cavalieri E.L. Tumor-initiating activity and carcinogenicity of dibenzo[a, l]pyrene versus 7,12-dimethylbenz[a]anthracene and benzo[a]pyrene at low-doses in mouse skin. Carcinogenesis 1993, 14:875-878.
18. IARC IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Certain polycyclic aromatic hydrocarbons and heterocyclic compounds. 1973, Volume 3.
19. IARC Some non-heterocyclic polycyclic aromatic hydrocarbons and some related exposures. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 2010, International Agency for Research on Cancer, Lyon, France.
20. Jepson G.W., Hoover D.K., Black R.K., McCafferty J.D., Mahle D.A., Gearhart J.M. A partition-coefficient determination method for nonvolatile chemicals in biological tissues. Fundam. Appl. Toxicol. 1994, 22:519-524.
21. Kim H.J., Bruckner J.V., Dallas C.E., Gallo J.M. Effect of dosing vehicles on the pharmacokinetics of orally-administered carbon-tetrachloride in rats. Toxicol. Appl. Pharmacol. 1990, 102:50-60.
22. Krzeminski J., Lin J.M., Amin S., Hecht S.S. Synthesis of fjord region diol expoxides as potential ultimate carcinogens of dibenzo[a, l]pyrene. Chem. Res. Toxicol. 1994, 7:125-129.
23. Lavoie E.J., He Z.M., Meegalla R.L., Weyand E.H. Exceptional tumor-initiating activity of 4-fluorobenzo[j]fluoranthene on mouse skin - comparison with benzo[j]fluoranthene, 10-fluorobenzo[j]fluoranthene, benzo[a]pyrene, dibenzo[a, l]pyrene and 7,12-dimehtylbenz[a]anthracene. Cancer Lett. 1993, 70:7-14.
24. Luch A., Platt K.L., Seidel A. Synthesis of fjord region tetraols and their use in hepatic biotransformation studies of dihydrodiols of benzo[c]chrysene, benzo[g]chrysene and dibenzo[a, l]pyrene. Carcinogenesis 1998, 19:639-648.
25. Moir D., Viau A., Chu I., Withey J., McMullen E. Pharmacokinetics of benzo[a]pyrene in the rat. J. Toxicol. Environ. Health A 1998, 53:507-530.
26. NIH Guide for the care and use of laboratory animals 2011, National Research Council, Washington, D.C.
27. Osinski M.A., Seifert T.R., Cox B.F., Gintant G.A. An improved method of evaluation of drug-evoked changes in gastric emptying in mice. J. Pharmacol. Toxicol. Meth. 2002, 47:115-120.
28. Palin K.J., Whalley D.R., Wilson C.G., Davis S.S., Phillips A.J. Determination of gastric-emptying profiles in the rat - influence of oil structure and volume. Int. J. Pharm. 1982, 12:315-322.
29. Phillips D.H. 50 years of benzo(alpha)pyrene. Nature 1983, 303:468-472.
30. Platt K.L., Dienes H.P., Tommasone M., Luch A. Tumor formation in the neonatal mouse bioassay indicates that the potent carcinogen dibenzo[def, p]chrysene (dibenzo[a, l]pyrene) is activated in vivo via its trans-11,12-dihydrodiol. Chem. Biol. Interact. 2004, 148:27-36.
31. Poulin P., Krishnan K. An algorithm for predicting tissue: Blood partition coefficients of organic chemicals from n-octanol: water partition coefficient data. J. Toxicol. Environ. Health 1995, 46:117-129.
32. Poulin P., Theil F.-P. A priori prediction of tissue:plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery. J. Pharm. Sci. 2000, 89:16-35.
33. Prahalad A.K., Ross J.A., Nelson G.B., Roop B.C., King L.C., Nesnow S., Mass M.J. Dibenzo[a, l]pyrene-induced DNA adduction, tumorigenicity, and Ki-ras oncogene mutations in strain A/J mouse lung. Carcinogenesis 1997, 18:1955-1963.
34. Roth R.A., Vinegar A. Action by the lungs on circulating xenobiotic agents, with a case study of physiologically based pharmacokinetic modeling of benzo(a)pyrene disposition. Pharmacol. Ther. 1990, 48:143-155.
35. Roth W.L., Freeman R.A., Wilson A.G.E. A physiologically based model for gastrointestinal absorption and excretion of chemicals carried by lipids. Risk Anal. 1993, 13:531-543.
36. Schlede E., Kuntzman R., Haber S., Conney A.H. Effect of enzyme induction on metabolism and tissue distribution of benzo(alpha)pyrene. Cancer Res. 1970, 30. 2893-&.
37. Sharma A.K., Kumar S., Amin S. A highly abbreviated synthesis of dibenzo[def, p]chrysene and its 12-methoxy derivative, a key precursor for the synthesis of the proximate and ultimate carcinogens of dibenzo[def, p]chrysene. J. Org. Chem. 2004, 69:3979-3982.
38. Shimada T., Gillam E.M.J., Oda Y., Tsumura F., Sutter T.R., Guengerich F.P., Inoue K. Metabolism of benzo[a]pyrene to trans-7,8-dihydroxy-7,8-dihydrobenzo[a]pyrene by recombinant human cytochrome P4501B1 and purified liver epoxide hydrolase. Chem. Res. Toxicol. 1999, 12:623-629.
39. Staats D.A., Fisher J.W., Connolly R.B. Gastrointestinal absorption of xenobiotics in physiologically based pharmacokinetic models - a 2-compartment description. Drug Metab. Dispos. 1991, 19:144-148.
40. Timchalk C., Nolan R.J., Mendrala A.L., Dittenber D.A., Brzak K.A., Mattsson J.L. A physiologically based pharmacokinetic and pharmacodynamic (PBPK/PD) model for the organophosphate insecticide chlorpyrifos in rats and humans. Toxicol. Sci. 2002, 66:34-53.
41. Trout D.L., Putney J.D., Conway E.S. Relative rates of gastric-emptying of glucose vs fat in rats fed non-liquid meals. Am. J. Physiol. 1978, 234:E660-E666.
42. U.S. EPA Dose-response analysis of ingested Benzo[a]pyrene (CAS No. 50-32-8). Human Health Assessment Group, Office of Health and Environmental Assessment, Washington, D.C 1991.
43. U.S.EPA Drinking water criteria document for polycyclic aromatic hydrocarbons (PAHs). Office of Health and Environmental Assessment, Environmental Criteria and Assessment Office, Cincinnati, OH for the Office of Water Regulations and Standards, Washington, D.C 1991.
44. Uno S., Dalton T.P., Derkenne S., Curran C.P., Miller M.L., Shertzer H.G., Nebert D.W. Oral exposure to benzo[a] pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. Mol. Pharmacol. 2004, 65:1225-1237.
45. Walker N.J., Gastel J.A., Costa L.T., Clark G.C., Lucier G.W., Sutter T.R. Rat CYP1b1 - an adrenal cytochrome-P450 that exhibits sex-dependent expression in livers and kidneys of TCDD-treated animals. Carcinogenesis 1995, 16:1319-1327.
46. Wiersma D.A., Roth R.A. The prediction of benzo[a]pyrene clearance by rat liver and lung from enzyme kinetic data. Mol. Pharmacol. 1983, 24:300-308.
47. Wiersma D.A., Roth R.A. Total-body clearance of circulating benzo(a)pyrene in conscious rats - effect of pretreatment with 3-methylcholanthrene and the role of liver and lung. J. Pharmacol. Exp. Ther. 1983, 226:661-667.
48. Willems B.A.T., Melnick R.L., Kohn M.C., Portier C.J. A physiologically based pharmacokinetic model for inhalation and intravenous administration of naphthalene in rats and mice. Toxicol. Appl. Pharmacol. 2001, 176:81-91.
49. Xue W., Warshawsky D. Metabolic activation of polycyclic and heterocyclic aromatic hydrocarbons and DNA damage: a review. Toxicol. Appl. Pharmacol. 2005, 206:73-93.
50. Yu Z., Loehr C.V., Fischer K.A., Louderback M.A., Krueger S.K., Dashwood R.H., Kerkvliet N.I., Pereira C.B., Jennings-Gee J.E., Dance S.T., Miller M.S., Bailey G.S., Williams D.E. In utero exposure of mice to dibenzo[a, l]pyrene produces lymphoma in the offspring: role of the aryl hydrocarbon receptor. Cancer Res. 2006, 66:755-762.
51. Zhang Q.Y., Dunbar D., Kaminsky L.S. Characterization of mouse small intestinal cytochrome P450 expression. Drug Metab. Dispos. 2003, 31:1346-1351.